Healthcare News

BioXcel Therapeutics intends to complete a court-supervised sale transaction, in an effort to maximize value for all stakeholders Teva Pharmaceuticals to serve as “stalking horse” bidder in a...

CDT Validates Enhanced Solid-Form Properties Within Its IP Portfolio

-- Chiesi’s abstract presentations highlight clinical insights and patient-reported outcomes in Fabry disease and alpha-mannosidosis -- -- Rooted in patient voice and scientific rigor, this research...

The SALWEEN study showed significant improvements in vision and retinal health1 More than 60% of Asian patients with polypoidal choroidal vasculopathy (PCV), an aggressive subtype of nAMD, treated...

-- Chiesi’s abstract presentations highlight clinical insights and patient-reported outcomes in Fabry disease and alpha-mannosidosis -- -- Rooted in patient voice and scientific rigor, this research...

EssilorLuxottica announces the launch of a share buyback program Paris, France (August 28, 2026 – 8:00am) – EssilorLuxottica announces the launch of a share buyback program, reflecting the Group’s...

EssilorLuxottica annonce le lancement d’un programme de rachat d’actions Paris, France (28 août 2026 – 8h00) – EssilorLuxottica annonce le lancement d’un programme de rachat d’actions qui traduit la...

EssilorLuxottica annuncia un programma di acquisto di azioni proprie Parigi, Francia (28 agosto 2026 – ore 8:00) – EssilorLuxottica annuncia il lancio di un programma di acquisto di azioni proprie...

OSE Immunotherapeutics to host a KOL webcast dedicated to lusvertikimab on September 2, 2026

NANTES, France, le 28 août 2026, 7h30 CET – OSE Immunotherapeutics SA (ISIN : FR0012127173 ; Mnemo : OSE) (la « Société »), annonce aujourd’hui que la Société organisera un webcast avec des experts...